The pharmaceutical packaging solutions provided by pharmaceutical packaging are 100% New Zealand-owned and made in an ISO9001-2008 facility in Auckland. Their products are from FDA/EU-compliant plastics and feature stacking lugs on bases and polypropylene lids. They are also made to withstand rigorous handling and storage conditions.
Drugs for pain usually contain a combination of codeine, caffeine, and muscle relaxants. Pharmac prefer those specific warnings be identifiable from other information on the labelling. Typically, the language is written for healthcare professionals and should promote safe use. Nevertheless, all users should be able to understand what specific warnings mean.
Pharmac prefers that the generic name appears prominently on at least three non-opposing faces of the outer packaging.
The generic name of a product must be clearly stated. This information must be legible and appear on at least three non-opposing faces of the outer packaging. Abbreviations are generally discouraged on consumer labels. The manufacturer is responsible for ensuring the information on their product is readable.
Regulatory requirements for drug labelling have changed. New regulations are intended to make the labelling process easier for manufacturers and patients. In addition, the FDA has issued guidance on labelling pharmaceutical drugs for human use. This guidance replaces the guidance document “Labelling of Drugs for Human Use”, published by Health Canada in 1989. Since then, the guidance document has been taken out of circulation.
Brand name requirements for prescription drugs differ from those for non-prescription products. Drugs are considered prescription if obtained from or administered by a health professional. In addition, the guidelines for labelling non-prescription drugs outline the specific requirements for drug name placement. These guidelines also address using “look-alike” and “sound-alike” names for health products.
Brand names for drug products should reflect the strength of the product. For example, chloramphenicol palmitate oral suspension should include its strength in milligrams per millilitre. In addition, combination products can contain an immediate-release medicinal ingredient and a modified-release medicinal ingredient, and identifying the combination should be indicated on the product label.
Pharmac prefers that the expiry date be visible and where printed in indelible ink.
Pharmacy is more likely to accept a label with an expiry date that is visible and printed in indelible ink than one that is not. For this reason, Pharmacy also prefers clear plastic labelling and contains inverted text colour for better contrast. They also prefer the expiry date displayed on a space designated for the patient label.
The expiry date should be printed in indelible ink to prevent counterfeiting and improve customer safety. In addition, the Pharmpac NZ pharmaceutical packaging Pharmacy recommends the following: the strength of the active pharmaceutical substance should be printed prominently on three non-opposing sides of the outer packaging. Similarly, the concentration should be indicated below the strength but less prominently. Multi-dose injectable products should also include the strength per unit volume.
The strength per dose should be prominently displayed on the label of insulin.
Pharmac also recommends that the name of the pharmaceutical be visible and indelible ink. These details are also necessary for the safe selection and use of the pharmaceutical. Regulatory agencies such as Medsafe have provided comprehensive guidelines on the minimum labelling requirements. In addition, Pharmac recommends that pharmaceuticals use generic names rather than proprietary names. In addition, it prefers that the pharmaceutical name be spatially close to its trade name.
In addition to this, Pharmac prefers to use labels with Spanish text. It is also important to make the packaging clear. During the evaluation process, Pharmac will consider labelling preferences and other factors outlined in the Annual Invitation to Tender or other procurement documents. It will continue to consider these preferences in line with its statutory objective – to achieve the best possible health outcomes from pharmaceutical treatment within available funding.
Pharmac prefers those specific warnings be identifiable from other information on labelling.
Pharmpac NZ pharmaceutical packaging has published guidance on labelling pharmaceutical products for human use, replacing an older guidance document issued by Health Canada in 1989. This guidance does not apply to disinfectants, drug products used for veterinary use, or products used in clinical trials. It contains examples of how specific warnings should appear on a label but is not a requirement for labelling.
Drugs for pain usually contain a combination of codeine, caffeine, and muscle relaxants. Pharmac prefers those specific warnings be identifiable from other information on the labelling. Typically, the language is written for healthcare professionals and should promote safe use. Nevertheless, all users should be able to understand what specific warnings mean.